ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Citius Oncology, Inc. (CTOR) shows an Average True Range (ATR) of 0.33 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 1.9M, indicating liquidity. These fundamental metrics provide insight into CTOR's underlying financial health and market activity.
Citius Oncology, Inc. (CTOR) technical indicators as of August 15, 2025: the SMA 20 is -7.33%, SMA 50 at -25.84%, and SMA 200 at 28.84%. The RSI 14 value is 41.49, suggesting its current momentum. These technical analysis signals help assess CTOR's price trends and potential future movements.
Citius Oncology, Inc. (CTOR) stock performance overview as of August 15, 2025: The 52-week high is $6.19 (currently -72.21% below), and the 52-week low is $0.551 (currently 212.39% above). Over the past year, CTOR's performance is -95.65%, compared to the S&P 500's 16.68% change.
According to market data, Citius Oncology, Inc. (CTOR) stock's recent performance metrics show that over the last month, CTOR is 12.1%, with a Year-to-Date (YTD) performance of 53.04%. Over the past year, the stock has seen a -95.65% change. These figures summarize CTOR's price movements across various periods, reflecting its historical returns.
According to current financial data, CTOR stock's P/E (TTM) ratio is -4.81, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for CTOR, including P/S (N/A), P/B (3.94), and P/FCF (-384.39), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.